VANGUARD GROUP INC 13D and 13G filings for Nektar Therapeutics:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 5:09 pm Sale |
2023-12-29 | 13G | Nektar Therapeutics NKTR |
VANGUARD GROUP INC | 802,858 6.310% |
-888 (-0.11%) |
Filing |
| 2023-07-10 10:41 am Sale |
2023-06-30 | 13G | Nektar Therapeutics NKTR |
VANGUARD GROUP INC | 803,746 6.370% |
-733,973 (-47.73%) |
Filing |
| 2023-02-09 11:27 am Purchase |
2022-12-30 | 13G | Nektar Therapeutics NKTR |
VANGUARD GROUP INC | 1,537,718 12.270% |
303,591 (+24.60%) |
Filing |
| 2022-01-10 11:49 am Purchase |
2021-12-31 | 13G | Nektar Therapeutics NKTR |
VANGUARD GROUP INC | 1,234,127 10.030% |
149,288 (+13.76%) |
Filing |
| 2021-02-10 11:28 am Purchase |
2020-12-31 | 13G | Nektar Therapeutics NKTR |
VANGUARD GROUP INC | 1,084,839 9.070% |
7,665 (+0.71%) |
Filing |